Logo image of ALXO

ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALXO - US00166B1052 - Common Stock

1.5 USD
+0.07 (+4.9%)
Last: 11/24/2025, 12:42:18 PM
Fundamental Rating

1

Taking everything into account, ALXO scores 1 out of 10 in our fundamental rating. ALXO was compared to 533 industry peers in the Biotechnology industry. ALXO has a bad profitability rating. Also its financial health evaluation is rather negative. ALXO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALXO had negative earnings in the past year.
In the past year ALXO has reported a negative cash flow from operations.
In the past 5 years ALXO always reported negative net income.
In the past 5 years ALXO always reported negative operating cash flow.
ALXO Yearly Net Income VS EBIT VS OCF VS FCFALXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ALXO has a worse Return On Assets (-130.57%) than 81.99% of its industry peers.
ALXO's Return On Equity of -241.09% is on the low side compared to the rest of the industry. ALXO is outperformed by 69.79% of its industry peers.
Industry RankSector Rank
ROA -130.57%
ROE -241.09%
ROIC N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALXO Yearly ROA, ROE, ROICALXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALXO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALXO Yearly Profit, Operating, Gross MarginsALXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

2

2. Health

2.1 Basic Checks

ALXO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALXO has been increased compared to 5 years ago.
The debt/assets ratio for ALXO is higher compared to a year ago.
ALXO Yearly Shares OutstandingALXO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALXO Yearly Total Debt VS Total AssetsALXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ALXO has an Altman-Z score of -14.40. This is a bad value and indicates that ALXO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ALXO (-14.40) is worse than 78.80% of its industry peers.
ALXO has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.15, ALXO is doing worse than 64.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -14.4
ROIC/WACCN/A
WACCN/A
ALXO Yearly LT Debt VS Equity VS FCFALXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ALXO has a Current Ratio of 2.40. This indicates that ALXO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALXO (2.40) is worse than 70.17% of its industry peers.
ALXO has a Quick Ratio of 2.40. This indicates that ALXO is financially healthy and has no problem in meeting its short term obligations.
ALXO has a worse Quick ratio (2.40) than 68.29% of its industry peers.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.4
ALXO Yearly Current Assets VS Current LiabilitesALXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

ALXO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.89%, which is quite impressive.
EPS 1Y (TTM)33.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALXO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.65% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.87%
EPS Next 2Y25.81%
EPS Next 3Y17.91%
EPS Next 5Y23.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALXO Yearly Revenue VS EstimatesALXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2030 2031 2032 20M 40M 60M 80M 100M
ALXO Yearly EPS VS EstimatesALXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALXO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALXO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALXO Price Earnings VS Forward Price EarningsALXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALXO Per share dataALXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ALXO's earnings are expected to grow with 17.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.81%
EPS Next 3Y17.91%

More info and screens

0

5. Dividend

5.1 Amount

ALXO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALX ONCOLOGY HOLDINGS INC

NASDAQ:ALXO (11/24/2025, 12:42:18 PM)

1.5

+0.07 (+4.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners50.31%
Inst Owner Change-4.41%
Ins Owners1.5%
Ins Owner Change9.59%
Market Cap80.33M
Revenue(TTM)N/A
Net Income(TTM)-108.01M
Analysts84
Price Target3.06 (104%)
Short Float %4.35%
Short Ratio3.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.65%
Min EPS beat(2)-9.62%
Max EPS beat(2)6.32%
EPS beat(4)2
Avg EPS beat(4)-1.58%
Min EPS beat(4)-22.55%
Max EPS beat(4)19.52%
EPS beat(8)5
Avg EPS beat(8)4.11%
EPS beat(12)8
Avg EPS beat(12)2.17%
EPS beat(16)9
Avg EPS beat(16)-0.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)33.33%
EPS NQ rev (1m)-2.13%
EPS NQ rev (3m)-4.92%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.79
P/tB 1.79
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0
BVpS0.84
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -130.57%
ROE -241.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2.4
Altman-Z -14.4
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)208.08%
Cap/Depr(5y)2095.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.31%
EPS Next Y31.87%
EPS Next 2Y25.81%
EPS Next 3Y17.91%
EPS Next 5Y23.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.23%
EBIT Next 3Y18.82%
EBIT Next 5YN/A
FCF growth 1Y13.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.7%
OCF growth 3YN/A
OCF growth 5YN/A

ALX ONCOLOGY HOLDINGS INC / ALXO FAQ

What is the fundamental rating for ALXO stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALXO.


What is the valuation status of ALX ONCOLOGY HOLDINGS INC (ALXO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALX ONCOLOGY HOLDINGS INC (ALXO). This can be considered as Overvalued.


How profitable is ALX ONCOLOGY HOLDINGS INC (ALXO) stock?

ALX ONCOLOGY HOLDINGS INC (ALXO) has a profitability rating of 0 / 10.


How financially healthy is ALX ONCOLOGY HOLDINGS INC?

The financial health rating of ALX ONCOLOGY HOLDINGS INC (ALXO) is 2 / 10.